| Identification | Back Directory | [Name]
N-Methyl-N′-[4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl]-thiourea | [CAS]
1251839-15-2 | [Synonyms]
SPA0355
SPA0355 >=98% (HPLC)
N-Methyl-N′-[4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl]-thiourea
Thiourea, N-methyl-N'-[4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl]- | [Molecular Formula]
C22H21N3O2S | [MDL Number]
MFCD22666401 | [MOL File]
1251839-15-2.mol | [Molecular Weight]
391.49 |
| Chemical Properties | Back Directory | [Boiling point ]
556.7±60.0 °C(Predicted) | [density ]
1.288±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble15mg/mL (clear solution) | [form ]
powder | [pka]
13.68±0.70(Predicted) | [color ]
white, to tan to gray |
| Hazard Information | Back Directory | [Uses]
SPA0355 is a thiourea derivative that has antioxidant and anti-inflammatory properties. SPA0355 inhibits the RANKL (receptor activator of nuclear factor κB ligand) induced osteoclast formation in primary bone marrow-derived macrophages. SPA0355 also suppresses the activation of the MAPKs, Akt, and NF-κB pathways. Additionally, SPA0355 promotes osteoblast differentiation, increases alkaline phosphatase activity, and enhances mineral nodule formation. SPA0355 can protect ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it useful for studying postmenopausal osteoporosis[1]. | [References]
[1] Sang Hoon Kim, et al. SPA0355 prevents ovariectomy-induced bone loss in mice. Korean J Physiol Pharmacol. 2018 Dec 26;23(1):47–54. |
|
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
| Company Name: |
TargetMol
|
| Telephone: |
400-821-0310 15002144251 |
| Website: |
www.targetmol.cn/ |
|